硼替佐米联合化疗治疗多发性骨髓瘤28例疗效分析

Efficacy analysis of bortezomib-based chemotherapy for 28 cases with multiple myeloma

目的观察以蛋白酶体抑制剂硼替佐米为主的化疗方案治疗多发性骨髓瘤（MM）的疗效和患者不良反应。方法28例MM患者接受以硼替佐米为主的联合方案化疗。疗效评定按照EBMT标准进行。结果28例MM患者中，初治20例，复发难治8例。25例可评估疗效，总反应率达100％（25／25），其中完全缓解（CR）5例，接近完全缓解（nCR）10例，部分缓解（PR）10例。主要不良反应包括周同神经病变、血小板减少、消化道反应及病毒感染，经对症处理后好转，一般不影响治疗。结论以硼替佐米为主的联合化疗治疗初治和复发难治MM起效较快，治疗反应率高，不良反应可耐受。

Objective To examine the efficacy and adverse reactions of bortezomib-based chemotherapy in treatment of multiple myeloma （MM）. Methods Twenty-eight patients with multiple myeloma received a joint chemotherapy containing bortezomib. The efficacy was determined according to EBMT criteria. Results 28 patients received the chemotherapy, 20 patients were newly diagnosed and 8 patients were relapsed or refractory. 25 patients can be evaluateed efficacy. The total response rate was 100 % （25/25）, consisting of 5 patients with complete response （CR）, 10 patients with almost complete remission （nCR）, 10 patients with partial remission （PR）. The main side effects include peripheral neuropathy, thrombocytopenia, gastrointestinal disorders and viral infections. These side effects were improved by symptomatic treatment and generally did not affect the treatment. Conclusion For the newly diagnosed and relapsed or refractory multiple myeloma cases, bortezomib-based chemotherapy is a safe and effective therapeutic drug with rapid onset, high treatment response rate, and adverse reaction can be tolerated.